Amicus Therapeutics is one of the leading biopharmaceutical company based in Cranbury, NJ, United States. Amicus Therapeutics went public in the year 2007 and had the trading symbol called FOLD. Previously, the trading symbol was planned as AMTX, but the plan was later withdrawn. Before the company went public, Amicus Therapeutics was funded by many different venture capital firms such as the famous Canaan Partners, Radius Ventures, and New Enterprise Associates. Amicus Therapeutics has been dedicated to developing drugs for the diseases that are rare, orphan, and terminal in nature.

 

 

The company is also known to offer highly advanced drugs for the disorders that in medical terms are collectively termed as Lysosomal Storage Disorders. The company follows the highly advanced mechanism for drug development, which is also known as the Chaperone Advanced Replacement Therapy, also known as CHART. The company’s product development platform is highly progressive and is primarily focused on developing therapies for enzyme replacement. At the moment, Amicus Therapeutics doesn’t do manufacturing on its own, but rely on the contract manufacturers for its production.

 

 

When Amicus Therapeutics started its operations, it had just one research site based in New Jersey. However, one more research facility was inducted in the year 2008 by Amicus Therapeutics in San Diego. Amicus Therapeutics started by the generous donations made by Michael J Fox Foundation of $500,000 and the famous David Geffen School of Medicine (YahooFinance). The grant of $210,000 was also provided by the Alzheimer’s Drug Discovery Foundation in the year 2010. Amicus Therapeutics was founded on the principle that it would focus all its energy, resources and influence to find the cure and drugs for the rare and orphan diseases. The company has made some considerable progress from the time it has started, and many of the drugs it has developed are licensed while few others are waiting for approval.

 

 

The primary product of Amicus Therapeutics that has become widely popular in the medical world is Migalastat (https://www.indeed.com/q-Amicus-Therapeutics-l-Cranbury,-NJ-jobs.html). It is a medication used to treat people suffering from the rare Fabry Disease. The company also develops drugs for Pompe disease, genetic skin diseases, and more.